Beam Therapeutics Inc.

What they do

Beam Therapeutics uses proprietary base editing technology, which chemically modifies a single DNA base without making a double-stranded break, to develop precision genetic medicines. The company pairs its base editors with ex vivo or in vivo delivery modalities, including lipid nanoparticles, and has internal manufacturing capabilities. Its lead programs include risto-cel (BEAM-101) for sickle cell disease, BEAM-302 for alpha-1 antitrypsin deficiency, and earlier-stage programs such as BEAM-304 in phenylketonuria and BEAM-301 in GSDIa.

Revenue drivers

• Collaboration and license revenue — The company's reported revenue is primarily from collaboration and license agreements, as it has no approved products; revenue has been highly variable, ranging from $51.8M in 2021 to $377.7M in 2023 and $139.7M in 2025.
• Risto-cel (BEAM-101) for sickle cell disease — A patient-specific autologous HSC therapy in Phase 1/2 BEACON trial; no product revenue yet, but a BLA submission is expected as early as year-end 2026.
• BEAM-302 for AATD — A liver-targeting LNP base editing therapy in Phase 1/2; the first patient was dosed in the global pivotal cohort in July 2026, with a potential accelerated approval path.
• Platform programs (BEAM-304, BEAM-301, BEAM-103) — Earlier-stage programs including BEAM-304 in PKU (IND cleared June 2026), BEAM-301 in GSDIa, and BEAM-103 in a Phase 1 healthy volunteer trial; these are pre-revenue and represent future potential.

Recent performance

For the second quarter of 2026, Beam reported revenue of $0.49 million, down from $31.7 million in the first quarter of 2026 and $114.1 million in the fourth quarter of 2025. Full-year 2025 revenue was $139.7 million, with a net loss of $80.0 million and diluted EPS of -$0.81. Operating cash flow was -$345.1 million for 2025, reflecting continued investment in clinical programs. As of June 30, 2026, the company had $1.07 billion in shareholder equity, $219.8 million in cash and equivalents, and $100.3 million in long-term debt.

Strategy

Beam is prioritizing its lead hematology and genetic disease programs, risto-cel and BEAM-302, while advancing a multi-wave strategy that includes ex vivo and in vivo base editing for sickle cell disease. The company is investing in targeted lipid nanoparticles for in vivo delivery to HSCs and its ESCAPE platform for non-genotoxic conditioning. It plans to expand the BEAM-302 Phase 1/2 trial to approximately 50 additional patients to support a future BLA, and it is initiating clinical start-up activities for BEAM-304 in PKU following IND clearance. Management expects a cash runway into mid-2029, ending Q2 2026 with $1.2 billion in cash, cash equivalents and marketable securities.

Risks

• Clinical and regulatory risk — Risto-cel and BEAM-302 are still in clinical trials, and their BLA submissions and potential approvals depend on successful outcomes and regulatory review.
• No approved products — Beam has no commercial products, and its revenue is derived from collaboration and license agreements, which can be volatile and may not be sustained.
• Significant cash burn — Operating cash flow was -$345.1 million in 2025, and continued investment in research, development and manufacturing could require additional financing.
• Competition and technological risk — Base editing is a relatively new field, and other gene editing approaches may prove safer, more effective, or reach the market sooner.

Outlook

Management expects to report updated BEAM-302 data at the ERS Congress in September 2026 and anticipates rapid enrollment in the pivotal cohort. The company expects first-in-human data for BEAM-301 in GSDIa and a BLA submission for risto-cel as early as year-end 2026. Beam states its cash runway is expected to support operating plans into mid-2029.